𝔖 Bobbio Scriptorium
✦   LIBER   ✦

French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients

✍ Scribed by Gérard Pons; M.C. Marchand; P. d'Athis; E. Sauvage; C. Foucard; P. Chaumet-Riffaud; A. Sautegeau; J. Navarro; G. Lenoir

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
50 KB
Volume
30
Category
Article
ISSN
8755-6863

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab in patients with primary progr
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Interferon-α does not improve outcome at
Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial
✍ Carol M. Black; Alan J. Silman; Ariane I. Herrick; Christopher P. Denton; Helen 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB

## Objective: To determine whether interferon-alpha (ifnalpha) reduces the severity of skin involvement in early (<3 years) diffuse scleroderma. ## Methods: In a randomized, placebo-controlled, double-blind trial, 35 patients with early scleroderma received subcutaneous injections of either ifnal